Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBITDA (2019 - 2026)

Biodesix filings provide 8 years of EBITDA readings, the most recent being -$6.2 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 32.13% to -$6.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$24.9 million, a 23.53% increase, with the full-year FY2025 number at -$27.9 million, up 19.2% from a year prior.
  • EBITDA hit -$6.2 million in Q1 2026 for Biodesix, down from -$2.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.0 million in Q4 2025 to a low of -$16.4 million in Q1 2023.
  • Median EBITDA over the past 5 years was -$9.1 million (2025), compared with a mean of -$9.4 million.
  • Biggest five-year swings in EBITDA: tumbled 159.02% in 2022 and later surged 70.42% in 2025.
  • Biodesix's EBITDA stood at -$13.9 million in 2022, then skyrocketed by 50.54% to -$6.9 million in 2023, then increased by 3.22% to -$6.6 million in 2024, then surged by 70.42% to -$2.0 million in 2025, then tumbled by 215.25% to -$6.2 million in 2026.
  • The last three reported values for EBITDA were -$6.2 million (Q1 2026), -$2.0 million (Q4 2025), and -$7.1 million (Q3 2025) per Business Quant data.